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Light therapy for nonseasonal 
major depressive disorder?
While bright light therapy already has a place in the 
treatment of seasonal affective disorder, a recent trial 
spotlights its utility beyond the winter months. 
PRACTICE CHANGER 
Consider treatment with bright light therapy, 
alone or in combination with fluoxetine, for 
patients with nonseasonal major depressive 
disorder (MDD).1
STRENGTH OF RECOMMENDATION
B: Based on a single moderate-quality ran-
domized control trial.
Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, 
fluoxetine, and the combination in patients with nonseasonal major 
depressive disorder: a randomized clinical trial. JAMA Psychiatry. 
2016;73:56-63.
ILLUSTRATIVE CASE 
A 38-year-old woman recently diagnosed 
with MDD without a seasonal pattern comes 
to see you for her treatment options. Her 
Hamilton Depression Rating Scale (HAM-D) 
is 22, and she is not suicidal. Should you 
consider bright light therapy in addition to 
pharmacotherapy?
MDD is one of the most common psychiatric illnesses in the United States, affecting approximately 
one in 5 adults at some point in their lives.2 
Selective serotonin reuptake inhibitors 
(SSRIs) and serotonin-norepinephrine reup-
take inhibitors are considered effective first-
line pharmacotherapy options for MDD.2,3 
Despite their effectiveness, however, studies 
have shown that only about 40% of patients 
with MDD achieve remission with first- or 
second-line drugs.2 In addition, pharma-
cologic agents have a higher frequency of 
treatment-associated adverse effects than 
fluorescent light therapy.4
A Cochrane systematic review of 20 stud-
ies (N=620) showed the effectiveness of com-
bined light therapy and pharmacotherapy 
in treating nonseasonal MDD, but found no 
benefit to light used as a monotherapy.5 How-
ever, the majority of the studies were of poor 
quality, occurred in the inpatient setting, and 
lasted fewer than 4 weeks. 
In a 5-week, controlled, double-blind 
trial not included in the Cochrane review, 
102 patients with nonseasonal MDD were 
randomized to receive either active treatment 
(bright light therapy) plus sertraline 50 mg 
daily or sham light treatment (using a dim red 
light) plus sertraline 50 mg daily. The inves-
tigators found a statistically significant larger 
reduction in depression score in the active 
treatment group than in the sham light group, 
based on the HAM-D, the Hamilton 6-Item 
Subscale, the Melancholia Scale, and the 
7 atypical items from the Structured Interview 
Guide for the Seasonal Affective Disorder ver-
sion of the HAM-D.6,7
STUDY SUMMARY
Light therapy improves depression  
without a seasonal component
This latest study was an 8-week random-
ized, double-blind, placebo- and sham- 
controlled clinical trial evaluating the benefit 
of light therapy with and without pharma-
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cotherapy for nonseasonal MDD.1 The in-
vestigators enrolled 122 adult patients (ages 
19-60 years) from outpatient psychiatry clin-
ics with a diagnosis of MDD (as diagnosed by 
a psychiatrist) and a HAM-D8 score of at least 
20. Subjects had to be off psychotropic medi-
cation for at least 2 weeks prior to the first vis-
it and were subsequently monitored for one 
week to identify spontaneous responders and 
to give patients time to better regulate their 
sleep-wake cycle (with the goal of sleeping 
only between 10:00 pm and 8:00 am daily). 
The investigators randomly assigned 
patients to one of 4 treatment groups: active 
light monotherapy (10,000-lux fluorescent 
white light for 30 min/d early in the morning) 
plus a placebo pill; fluoxetine 20 mg/d plus 
sham light therapy; placebo pills with sham 
light therapy; and combined active light ther-
apy with fluoxetine 20 mg daily. Sham light 
therapy consisted of the use of an inactivated 
negative ion generator, used in the same fash-
ion as a light box. All patients were analyzed 
based on modified intention to treat.
The investigators monitored patients 
for adherence to active and sham treatment 
by review of their daily logs of device treat-
ment times. Pill counts were used to assess 
medication adherence. The primary outcome 
at 8 weeks was the change from baseline in 
the Montgomery-Asberg Depression Rating 
Scale (MADRS), a 10-item questionnaire with 
a worst score of 60.9  Secondary outcomes 
were treatment response (≥50% MADRS 
score reduction) and remission (≤10 MADRS 
score) at the final 8th-week visit. MADRS 
scoring was used because of its higher sen-
sitivity to treatment-induced changes and its 
high correlation with the HAM-D scale.
At the end of 8 weeks, the mean (stan-
dard deviation [SD]) changes in MADRS 
scores from baseline were: light mono-
therapy 13.4 (7.5), fluoxetine monotherapy 
8.8 (9.9), combination therapy 16.9 (9.2), 
and placebo 6.5 (9.6). The improvement was 
significant in the light monotherapy treat-
ment group vs the placebo group (P=.006), 
in the combination treatment group vs the 
placebo group (P<.001), and in the combina-
tion group vs the fluoxetine treatment group 
(P=.02), but not for the fluoxetine treatment 
group vs the placebo group (P=.32). The effect 
sizes vs placebo were: fluoxetine, d=0.24 (95% 
confidence interval [CI], −0.27 to 0.74); light 
monotherapy, 0.80 (95% CI, 0.28 to 1.31); and 
combination therapy, 1.11 (95% CI, 0.54 to 
1.64). Effect sizes of more than 0.8 are often 
considered large.10
The treatment response (≥50% MADRS 
improvement) rate was highest in the com-
bination treatment group (75.9%) with re-
sponse rates to light monotherapy, placebo, 
and fluoxetine monotherapy of 50%, 33.3%, 
and 29%, respectively. There was a signifi-
cant response effect for the combination vs 
placebo treatment group (P=.005). Similarly, 
there was a higher remission rate in the com-
bination treatment group (58.6%) than in the 
placebo, light monotherapy, or fluoxetine 
treatment groups (30%, 43.8%, and 19.4%, 
respectively) with a significant effect for the 
combination vs placebo treatment group 
(P=.02).
Combination therapy was superior to 
placebo in treatment response (≥50% re-
duction in the MADRS score) and remis-
sion (MADRS ≤10) with numbers needed to 
treat of 2.4 (95% CI, 1.6-5.8) and 3.5 (95% CI, 
2.0-29.9), respectively.
By the end of the 8-week study period, 
16 of 122 patients had dropped out; 2 reported 
lack of efficacy, 5 reported adverse effects, and 
the remainder cited administrative reasons, 
were lost to follow-up, or withdrew consent. 
WHAT’S NEW?
New evidence  
on a not-so-new treatment
We now have evidence that bright light ther-
apy, either alone or in combination with 
fluoxetine, is efficacious in increasing the re-
mission rate of nonseasonal MDD.
 CAVEATS
Choice of SSRI, geography, and trial  
duration may have affected results
A single SSRI (fluoxetine) was used in this 
study; other more potent SSRIs might work 
better. This study was conducted in southern 
Canada, and light therapy may not demon-
strate as large a benefit in regions located far-
ther south. The study excluded pregnant and 
breastfeeding women. 
Seventy-six  
percent  
of patients  
treated with 
fluoxetine  
and light 
therapy saw 
at least a 50% 
improvement in 
their depression 
scores.
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We now have 
evidence that 
bright light  
therapy,  
alone or in 
combination 
with fluoxetine, 
is efficacious in 
increasing the 
remission rate 
of nonseasonal 
major  
depressive  
disorder.
The trial duration was relatively short, 
and the investigators did not attain their pre-
planned sample size for the study, which lim-
ited the power to detect clinically significant 
seasonal treatment effects and differences 
between the fluoxetine and placebo groups, 
regardless of whether they received active 
phototherapy. 
Also, it’s worth noting that there were 
trends for some adverse events (nausea, heart-
burn, weight gain, agitation, sexual dysfunc-
tion, and skin rash) to occur less frequently in 
the combination group than in the fluoxetine 
monotherapy group. Possible explanations 
are that the study had inadequate power, that 
the sham treatment did not adequately blind 
patients, or that light therapy can ameliorate 
some of the adverse effects of fluoxetine.
 CHALLENGES TO IMPLEMENTATION
Commercial insurance doesn’t  
usually cover light therapy
Bright light therapy is fairly safe, and some 
evidence exists supporting its use in the treat-
ment of nonseasonal MDD; however, the 
data for its use in this area are limited.11 Since 
only a few studies have tested light therapy 
for nonseasonal MDD, significant uncertain-
ty remains about patient selection, as well as 
optimal dose, timing, and duration of light 
therapy in the management of nonseasonal 
MDD.12 Although the risks associated with 
bright light therapy are minimal, the therapy 
can lead to mania or hypomania,3 so clini-
cians need to monitor for such effects when 
initiating therapy. 
Lastly, commercial insurance does not 
usually cover light therapy. The average price 
of the bright light devices, which can be found 
in medical supply stores and online outlets, 
ranges between $118 and $237.4,12 However, 
such devices are reusable, making the amor-
tized cost almost negligible.13                  JFP
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